|
1
|
Tao Z, Shi A, Lu C, Song T, Zhang Z and
Zhao J: Breast cancer: Epidemiology and etiology. Cell Biochem
Biophys. 72:333–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
An overview of the randomised trials. Lancet. 365:1687–1717. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carrara GF, Scapulatempo-Neto C,
Abrahão-Machado LF, Brentani MM, Nunes JS, Folgueira MA and Vieira
RA: Breast-conserving surgery in locally advanced breast cancer
submitted to neoadjuvant chemotherapy. Safety and effectiveness
based on ipsilateral breast tumor recurrence and long-term
follow-up. Clinics (Sao Paulo). 72:134–142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tafe LJ: Molecular mechanisms of therapy
resistance in solid tumors: Chasing ‘moving’ targets. Virchows
Arch. 471:155–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nguyen LV, Vanner R, Dirks P and Eaves CJ:
Cancer stem cells: An evolving concept. Nat Rev Cancer. 12:133–143.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clevers H: The cancer stem cell: Premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niero EL, Rocha-Sales B, Lauand C, Cortez
BA, de Souza MM, Rezende-Teixeira P, Urabayashi MS, Martens AA,
Neves JH and Machado-Santelli GM: The multiple facets of drug
resistance: One history, different approaches. J Exp Clin Cancer
Res. 33:372014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luo H, Tu G, Liu Z and Liu M:
Cancer-associated fibroblasts: A multifaceted driver of breast
cancer progression. Cancer Lett. 361:155–163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tao L, Huang G, Song H, Chen Y and Chen L:
Cancer associated fibroblasts: An essential role in the tumor
microenvironment. Oncol Lett. 14:2611–2620. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ashida S, Kawada C and Inoue K: Stromal
regulation of prostate cancer cell growth by mevalonate pathway
enzymes HMGCS1 and HMGCR. Oncol Lett. 14:6533–6542. 2017.PubMed/NCBI
|
|
11
|
Du H and Che G: Genetic alterations and
epigenetic alterations of cancer-associated fibroblasts. Oncol
Lett. 13:3–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dangi-Garimella S, Krantz SB, Barron MR,
Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ and Munshi HG:
Three-dimensional collagen I promotes gemcitabine resistance in
pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Cancer Res. 71:1019–1028. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burdelya LG, Komarova EA, Hill JE, Browder
T, Tararova ND, Mavrakis L, DiCorleto PE, Folkman J and Gudkov AV:
Inhibition of p53 response in tumor stroma improves efficacy of
anticancer treatment by increasing antiangiogenic effects of
chemotherapy and radiotherapy in mice. Cancer Res. 66:9356–9361.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rong G, Kang H, Wang Y, Hai T and Sun H:
Candidate markers that associate with chemotherapy resistance in
breast cancer through the study on Taxotere-induced damage to tumor
microenvironment and gene expression profiling of
carcinoma-associated fibroblasts (CAFs). PLoS One. 8:e709602013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roberti MP, Arriaga JM, Bianchini M,
Quintá HR, Bravo AI, Levy EM, Mordoh J and Barrio MM: Protein
expression changes during human triple negative breast cancer cell
line progression to lymph node metastasis in a xenografted model in
nude mice. Cancer Biol Ther. 13:1123–1140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chabottaux V and Noel A: Breast cancer
progression: Insights into multifaceted matrix metalloproteinases.
Clin Exp Metastasis. 24:647–656. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li K, Kang H, Wang Y, Hai T, Rong G and
Sun H: Letrozole-induced functional changes in carcinoma-associated
fibroblasts and their influence on breast cancer cell biology. Med
Oncol. 33:642016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aboussekhra A: Role of cancer-associated
fibroblasts in breast cancer development and prognosis. Int J Dev
Biol. 55:841–849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sambi M, Haq S, Samuel V, Qorri B, Haxho
F, Hill K, Harless W and Szewczuk MR: Alternative therapies for
metastatic breast cancer: Multimodal approach targeting tumor cell
heterogeneity. Breast Cancer (Dove Med Press). 9:85–93.
2017.PubMed/NCBI
|
|
21
|
Kubo N, Araki K, Kuwano H and Shirabe K:
Cancer-associated fibroblasts in hepatocellular carcinoma. World J
Gastroenterol. 22:6841–6850. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Madar S, Goldstein I and Rotter V: ‘Cancer
associated fibroblasts’-more than meets the eye. Trends Mol Med.
19:447–453. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Junttila MR and de Sauvage FJ: Influence
of tumour micro-environment heterogeneity on therapeutic response.
Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Perez EA: Impact, mechanisms, and novel
chemotherapy strategies for overcoming resistance to anthracyclines
and taxanes in metastatic breast cancer. Breast Cancer Res Treat.
114:195–201. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dittmer J and Leyh B: The impact of tumor
stroma on drug response in breast cancer. Semin Cancer Biol.
31:3–15. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shekhar MP, Santner S, Carolin KA and Tait
L: Direct involvement of breast tumor fibroblasts in the modulation
of tamoxifen sensitivity. Am J Pathol. 170:1546–1560. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun Y, Campisi J, Higano C, Beer TM,
Porter P, Coleman I, True L and Nelson PS: Treatment-induced damage
to the tumor microenvironment promotes prostate cancer therapy
resistance through WNT16B. Nat Med. 18:1359–1368. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hanker AB, Estrada MV, Bianchini G, Moore
PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, et al:
Extracellular matrix/integrin signaling promotes resistance to
combined inhibition of HER2 and PI3K in HER2+ breast
cancer. Cancer Res. 77:3280–3292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Faller WJ, Rafferty M, Hegarty S, Gremel
G, Ryan D, Fraga MF, Esteller M, Dervan PA and Gallagher WM:
Metallothionein 1E is methylated in malignant melanoma and
increases sensitivity to cisplatin-induced apoptosis. Melanoma Res.
20:392–400. 2010.PubMed/NCBI
|
|
30
|
Iyengar P, Combs TP, Shah SJ, Gouon-Evans
V, Pollard JW, Albanese C, Flanagan L, Tenniswood MP, Guha C,
Lisanti MP, et al: Adipocyte-secreted factors synergistically
promote mammary tumorigenesis through induction of anti-apoptotic
transcriptional programs and proto-oncogene stabilization.
Oncogene. 22:6408–6423. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Irwin WA, Bergamin N, Sabatelli P,
Reggiani C, Megighian A, Merlini L, Braghetta P, Columbaro M,
Volpin D, Bressan GM, et al: Mitochondrial dysfunction and
apoptosis in myopathic mice with collagen VI deficiency. Nat Genet.
35:367–371. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tokes AM, Szasz AM, Farkas A, Toth AI,
Dank M, Harsanyi L, Molnar BA, Molnar IA, Laszlo Z, Rusz Z and
Kulka J: Stromal matrix protein expression following preoperative
systemic therapy in breast cancer. Clin Cancer Res. 15:731–739.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sherman-Baust CA, Weeraratna AT, Rangel
LB, Pizer ES, Cho KR, Schwartz DR, Shock T and Morin PJ: Remodeling
of the extracellular matrix through overexpression of collagen VI
contributes to cisplatin resistance in ovarian cancer cells. Cancer
Cell. 3:377–386. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tatti O, Vehvilainen P, Lehti K and
Keski-Oja J: MT1-MMP releases latent TGF-beta1 from endothelial
cell extracellular matrix via proteolytic processing of LTBP-1. Exp
Cell Res. 314:2501–2514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu Z, Wang S, Wu M, Zeng W, Wang X and
Dong Z: TGFβ1 and HGF protein secretion by esophageal squamous
epithelial cells and stromal fibroblasts in oesophageal
carcinogenesis. Oncol Lett. 6:401–406. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bates AL, Pickup MW, Hallett MA, et al:
Stromal matrix metalloproteinase 2 regulates collagen expression
and promotes the outgrowth of experimental metastases. J Pathol.
2015.235(5): 773–783. View Article : Google Scholar : PubMed/NCBI
|
